

Please type a plus sign (+) inside the



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|-------------|--------------------------|--------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | (NOT YET ASSIGNED) |
| | | Filing Date | July 5, 2001 |
| | | First Named Inventor | Yoichi FUJII |
| | | Group Art Unit | 1648 |
| Examiner Name | U. Winkler | | |
| Sheet 2 | of 2 | Attorney Docket Number | NZK-128-1 |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| UW | | FUJII, Y., ET AL., "Biological Overview of HIV Accessory Protein Nef," <u>Saibo Kogaku</u> , 1997, pp. 94-99, vol. 16, no. 1 | |
| | | LIU ET AL., "Binding of HIV-1 Nef to a novel thioesterase enzyme correlates with Nef-mediated CD4 down-regulation", <u>The Journal of biological Chemistry</u> , 1997, pp. 13779-13785, Vol. 272 | |
| | | CAWTHON ET AL., "cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene", <u>Genomics</u> , 1991, pp. 446-460, Vol. 9 | |
| | | AHN ET AL., "The structural and functional diversity of dystrophin", <u>Nature Genetics</u> , 1993, pp. 283-291, Vol. 3 | |
| | | OKADA, H., ET AL., "Inhibition of HIV-1 Nef induced apoptosis of uninfected human blood cells by serine/threonine protein kinase inhibitors, fasudil hydrochloride and M3", <u>FEBS LETTERS</u> , 2-6-98, PPS. 363-367, Vol. 422, No. 3, XP002115665, Amsterdam, NL | |
| | | LUO T., ET AL., "Infectivity enhancement by immunodeficiency virus type 1 Nef is independent of its association with a cellular serine/threonine kinase", <u>Journal of Virology</u> , 1997, pp. 9524-9530, Vol. 71, No. 12, XP002115666, US | |
| | | ROSSI, F., ET AL., "H ₃ N3 proteasomal subunit as a target for human immunodeficiency virus type 1 Nef protein", <u>Virology</u> , 1997, pp. 33-45, Vol. 237, No. 1, XP002115667, Orlando, US | |
| | | SMITH, B.L., ET AL., "The HIV Nef protein associates with protein kinase C theta", <u>Journal of Biological Chemistry</u> , 1996, pp. 16753-16757, Vol. 271, No. 28, XP002115668, MD, US | |
| | | DE REUCK, ET AL., "A double-blind study of neurotrophin in patients with acute ischemic stroke," <u>Acta Neurol Scand</u> , 1994, pp. 329-335, 89 | |
| | | | |


| | | | |
|--------------------|--------------------|-----------------|----------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 11/25/02 |
|--------------------|--------------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside the []



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------|--------------------------|--------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | (NOT YET ASSIGNED) |
| | | Filing Date | July 5, 2001 |
| | | First Named Inventor | Yoichi FUJII |
| | | Group Art Unit | 1648 |
| Examiner Name | U. Winkler | | |
| Attorney Docket Number | NZK-128-1 | | |
| Sheet | 1 | of | 2 |



| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| UW | | 4,816,397 | | Michael A. BOSS et al. | Mar. 28, 1989 | |
| | | 4,816,567 | | Shmuel CABILLY et al. | Mar. 28, 1989 | |
| | | 5,225,539 | | Gregory Paul WINTER | July 6, 1993 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|-------------------------|--------------|-----------------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Office ³ | Number | Kind Code ⁵ (if known) | | | |
| UW | | EP | 0 120 694 B1 | | Celltech Limited | Oct. 3, 1984 | |
| | | EP | 0 125 023 B1 | | Genentech, Inc. | Nov. 14, 1984 | |
| | | EP | 0 239 400 A2 | | Gregory Paul WINTER | Sept. 30, 1987 | |
| | | WO | 86/01533 | | Celltech Limited | Mar. 13, 1986 | |
| | | WO | 98 13377 | | Blomolecular Research Institute Ltd. | Apr. 2, 1998 | |
| | | FR | 2 720 068 | | Institut National de la Sante et de la Recherche Medicale | Nov. 24, 1995 | |
| | | JP | 04360838 | | Sanyo Kokusaku Pulp Co., Ltd. | Dec. 14, 1992 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| | | | |
|--------------------|--------------------|-----------------|----------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 11/25/02 |
|--------------------|--------------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.